Uniqure NV
QURE25.650USD
+1.130+4.61%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
More Details of Uniqure NV Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Uniqure NV Info
Ticker SymbolQURE
Company nameUniqure NV
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Number of employees209
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressPaasheuvelweg 25a
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1105 BP
Phone31202406000
Websitehttps://www.uniqure.com/
Ticker SymbolQURE
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Company Executives of Uniqure NV
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+5858.00%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-4670.00%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Other
64.55%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Other
64.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
41.44%
Investment Advisor
27.86%
Hedge Fund
19.42%
Corporation
3.83%
Research Firm
3.16%
Venture Capital
1.48%
Individual Investor
1.47%
Pension Fund
0.91%
Private Equity
0.89%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
422
59.36M
95.29%
-2.44M
2025Q3
368
55.15M
89.53%
-7.50M
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.55M
8.9%
+4.74M
+591.04%
Sep 30, 2025
Avoro Capital Advisors LLC
4.44M
7.13%
+819.44K
+22.61%
Sep 30, 2025
RTW Investments L.P.
4.42M
7.1%
-733.26K
-14.22%
Sep 30, 2025
EcoR1 Capital, LLC
3.99M
6.4%
--
--
Sep 30, 2025
abrdn Inc.
2.94M
4.72%
+189.03K
+6.87%
Sep 30, 2025
Bristol Myers Squibb
2.39M
3.83%
--
--
Sep 30, 2024
Franklin Advisers, Inc.
1.98M
3.17%
+369.97K
+23.05%
Sep 30, 2025
State Street Investment Management (US)
1.44M
2.32%
+301.20K
+26.36%
Sep 30, 2025
Jennison Associates LLC
999.48K
1.6%
+859.42K
+613.61%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
2.12%
+68.87K
+5.49%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Genomics & Biotechnology ETF
3.77%
WisdomTree BioRevolution Fund
3.51%
Virtus LifeSci Biotech Clinical Trials ETF
2.87%
Invesco NASDAQ Future Gen 200 ETF
2.23%
Alger Mid Cap 40 ETF
2.06%
State Street SPDR S&P Biotech ETF
1.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
ProShares Ultra Nasdaq Biotechnology
0.36%
Invesco Nasdaq Biotechnology ETF
0.36%
Franklin Genomic Advancements ETF
0.34%
View more
Global X Genomics & Biotechnology ETF
Proportion3.77%
WisdomTree BioRevolution Fund
Proportion3.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion2.87%
Invesco NASDAQ Future Gen 200 ETF
Proportion2.23%
Alger Mid Cap 40 ETF
Proportion2.06%
State Street SPDR S&P Biotech ETF
Proportion1.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.84%
ProShares Ultra Nasdaq Biotechnology
Proportion0.36%
Invesco Nasdaq Biotechnology ETF
Proportion0.36%
Franklin Genomic Advancements ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
